Contributors: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD); Institut Pasteur de Lille; Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire Lille (CHRU Lille); Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 (EGID); Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS); Thérapie cellulaire du diabète; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé; Department of Endocrinology, Diabetology and Metabolism Antwerp, Belgium; Antwerp University Hospital Edegem (UZA); Department of Gastroenterology and Hepatology Antwerp, Belgium; ANR-16-RHUS-0006,PreciNASH,PreciNASH(2016); European Project: 694717,H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) ,ImmunoBile(2016)
نبذة مختصرة : International audience ; Non-Alcoholic SteatoHepatitis (NASH) is considered as a pivotal stage in Non-Alcoholic Fatty Liver Disease (NAFLD) progression, as it paves the way for severe liver injuries such as fibrosis and cirrhosis. The etiology of human NASH is multi-factorial and identifying reliable molecular players and/or biomarkers has proven difficult. Together with the inappropriate consideration of risk factors revealed by epidemiological studies (altered glucose homeostasis, obesity, ethnicity, sex…), the limited availability of representative NASH cohorts with associated liver biopsies, the gold standard for NASH diagnosis, probably explains the poor overlap between published "omics"-defined NASH signatures.
_1.png)
Processing Request
No Comments.